$HCAT
Health Catalyst Inc Stock $hcat

$hcat Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000163642222000011 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$64.72M	$241.9M	$53.28M
YoY Change	21.46%	28.11%	22.48%
Cost Of Revenue	$33.78M	$124.2M	$26.53M
YoY Change	27.34%	26.57%	29.35%
Gross Profit	$30.93M	$117.8M	$26.75M
YoY Change	15.64%	29.69%	16.35%
Gross Profit Margin	47.8%	48.68%	50.21%
Selling, General & Admin	$36.60M	$161.0M	$27.83M
YoY Change	31.51%	40.39%	30.96%
% of Gross Profit	118.32%	136.69%	104.04%
Research & Development	$17.03M	$62.73M	$14.98M
YoY Change	13.7%	17.22%	14.88%
% of Gross Profit	55.06%	53.27%	56.0%
Depreciation & Amortization	$10.92M	$5.500M	$7.780M
YoY Change	40.41%	89.66%	228.27%
% of Gross Profit	35.32%	4.67%	29.08%
Operating Expenses	$64.56M	$261.2M	$65.67M
YoY Change	-1.7%	39.77%	79.13%
Operating Profit	-$33.62M	-$143.7M	-$38.92M
YoY Change	-13.61%	49.44%	184.71%
Interest Expense	-$4.390M	-$16.48M	-$4.050M
YoY Change	8.4%	42.09%	710.0%
% of Operating Profit
Other Income/Expense, Net	$14.00K	$24.00K	-$20.00K
YoY Change	-170.0%	-76.0%	-300.0%
Pretax Income	-$49.14M	-$160.1M	-$42.99M
YoY Change	14.31%	37.79%	203.39%
Income Tax	-$149.0K	-$6.900M	$20.00K
% Of Pretax Income
Net Earnings	-$48.99M	-$153.2M	-$43.02M
YoY Change	13.88%	33.21%	201.47%
Net Earnings / Revenue	-75.7%	-63.33%	-80.74%
Basic Earnings Per Share		-$3.23
Diluted Earnings Per Share	-$939.1K	-$3.23	-$1.010M
COMMON SHARES
Basic Shares Outstanding	52.06M shares	47.49M shares	42.50M shares
Diluted Shares Outstanding		47.49M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$445.0M	$445.0M	$270.9M
YoY Change	64.26%	64.26%	18.66%
Cash & Equivalents	$193.2M	$193.2M	$91.95M
Short-Term Investments	$251.8M	$251.8M	$178.9M
Other Short-Term Assets	$14.61M	$14.61M	$10.60M
YoY Change	37.82%	37.82%	26.19%
Inventory
Prepaid Expenses
Receivables	$48.80M	$48.80M	$48.30M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$508.4M	$508.4M	$329.8M
YoY Change	54.15%	54.15%	24.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.32M	$44.45M	$12.86M
YoY Change	81.26%	18.22%	199.49%
Goodwill	$170.0M		$107.8M
YoY Change	57.64%		2818.84%
Intangibles	$104.8M		$98.92M
YoY Change	5.93%		287.39%
Long-Term Investments
YoY Change
Other Assets	$4.496M	$4.496M	$3.606M
YoY Change	24.68%	24.89%	345.19%
Total Long-Term Assets	$323.7M	$323.7M	$247.9M
YoY Change	30.56%	30.58%	550.41%
TOTAL ASSETS
Total Short-Term Assets	$508.4M	$508.4M	$329.8M
Total Long-Term Assets	$323.7M	$323.7M	$247.9M
Total Assets	$832.1M	$832.1M	$577.7M
YoY Change	44.03%	44.04%	91.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.693M	$4.693M	$5.332M
YoY Change	-11.98%	-11.45%	47.21%
Accrued Expenses	$27.15M	$27.15M	$19.10M
YoY Change	42.15%	42.15%	61.86%
Deferred Revenue	$56.63M		$47.15M
YoY Change	20.12%		53.8%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$93.05M	$93.05M	$88.04M
YoY Change	5.7%	5.74%	82.58%
LONG-TERM LIABILITIES
Long-Term Debt	$180.9M	$180.9M	$169.0M
YoY Change	7.07%	7.07%	250.61%
Other Long-Term Liabilities	$113.0K	$36.01M	$2.227M
YoY Change	-94.93%	-19.27%	583.13%
Total Long-Term Liabilities	$181.1M	$216.9M	$171.2M
YoY Change	5.74%	1.57%	252.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.05M	$93.05M	$88.04M
Total Long-Term Liabilities	$181.1M	$216.9M	$171.2M
Total Liabilities	$310.0M	$310.0M	$301.6M
YoY Change	2.77%	2.78%	196.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$878.9M		-$725.7M
YoY Change	21.11%		18.86%
Common Stock	$53.00K		$43.00K
YoY Change	23.26%		16.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$522.1M	$522.1M	$276.1M
YoY Change
Total Liabilities & Shareholders Equity	$832.1M	$832.1M	$577.7M
YoY Change	44.03%	44.04%	91.08%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$48.99M	-$153.2M	-$43.02M
YoY Change	13.88%	33.21%	201.47%
Depreciation, Depletion And Amortization	$10.92M	$5.500M	$7.780M
YoY Change	40.41%	89.66%	228.27%
Cash From Operating Activities	-$9.775M	-$23.12M	-$4.140M
YoY Change	136.11%	-11.57%	-68.3%
INVESTING ACTIVITIES
Capital Expenditures	-$3.730M	$10.45M	-$7.150M
YoY Change	-47.83%	34.41%	677.17%
Acquisitions		$46.76M
YoY Change		-54.0%
Other Investing Activities	-$72.95M	-$121.2M	-$14.76M
YoY Change	394.26%	68.12%	-30.18%
Cash From Investing Activities	-$76.68M	-$139.7M	-$21.91M
YoY Change	249.99%	69.17%	-0.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$245.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.916M	$264.1M	6.740M
YoY Change	-41.9%	44.62%	512.73%
NET CHANGE
Cash From Operating Activities	-9.775M	-$23.12M	-4.140M
Cash From Investing Activities	-76.68M	-$139.7M	-21.91M
Cash From Financing Activities	3.916M	$264.1M	6.740M
Net Change In Cash	-82.54M	$101.3M	-19.31M
YoY Change	327.46%	37.0%	-43.26%
FREE CASH FLOW
Cash From Operating Activities	-$9.775M	-$23.12M	-$4.140M
Capital Expenditures	-$3.730M	$10.45M	-$7.150M
Free Cash Flow	-$6.045M	-$33.57M	$3.010M
YoY Change	-300.83%	-1.03%	-124.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001636422
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38993
CY2021	dei	Entity Registrant Name EntityRegistrantName	HEALTH CATALYST, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3337483
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84095
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	10897 South River Front Parkway #300
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South Jordan
CY2021	dei	City Area Code CityAreaCode	801
CY2021	dei	Local Phone Number LocalPhoneNumber	708-6800
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	HCAT
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2500000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53347231	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193227000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91954000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	251754000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	178917000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48801000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48296000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14609000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10632000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	508391000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	329799000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23316000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12863000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21133000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24729000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	104788000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	98921000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	169972000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	107822000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4496000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3606000	USD
CY2021Q4	us-gaap	Assets Assets	832096000	USD
CY2020Q4	us-gaap	Assets Assets	577740000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4693000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5332000	USD
CY2021Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23725000	USD
CY2020Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	16510000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	56632000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	47145000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3425000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2622000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4576000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	14427000	USD
CY2021Q4	hcat	Business Combination Consideration Payable Current BusinessCombinationConsiderationPayableCurrent	0	USD
CY2020Q4	hcat	Business Combination Consideration Payable Current BusinessCombinationConsiderationPayableCurrent	2000000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93051000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	88036000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	180942000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	168994000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	929000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1878000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20244000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23669000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	14719000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16837000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	113000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2227000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	309998000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	301641000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52622080	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52622080	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43376848	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43376848	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	43000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1400972000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1001645000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	47284000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62733000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-878860000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-725650000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-67000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	61000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	522098000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	276099000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	832096000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	577740000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	241926000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	188845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154941000	USD
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	124354000	USD
CY2020	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	98077000	USD
CY2019	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	75345000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	75027000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	55411000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1670000	USD
CY2021	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	16458000	USD
CY2020	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	11572000	USD
CY2019	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	3419000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-160108000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-116211000	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-59954000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6898000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1194000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	142000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-115017000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-60096000	USD
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2019	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	180826000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-153210000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-115017000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-240922000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.91
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.91
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.86
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.86
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47495000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47495000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39541000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39541000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18741000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18741000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	20036000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-115017000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-60096000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-102000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-59000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	75000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-26000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	48000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-153338000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-115028000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60023000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-374768000	USD
CY2019	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	180826000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	602744000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2656000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17844000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2978000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-60096000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	73000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	200644000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	72457000	USD
CY2020	hcat	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Net Of Issuance Costs AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtNetOfIssuanceCosts	61213000	USD
CY2020	hcat	Adjustments To Additional Paid In Capital Purchase Of Capped Called Related To Issuance Of Convertible Senior Notes AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalledRelatedToIssuanceOfConvertibleSeniorNotes	21743000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36264000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4273000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38138000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-115017000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	276099000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	245180000	USD
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	43104000	USD
CY2021	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	20083000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	14088000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11948000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8054000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1081000	USD
CY2021	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3585000	USD
CY2020	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-4303000	USD
CY2019	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3460000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1800000	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20350000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4837000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65781000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-128000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	522098000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-115017000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-60096000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	65145000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	37957000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	17844000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37528000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18725000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9212000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53517000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46252000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	85934000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59240000	USD
CY2020	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	863000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31713000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37528000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18725000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9212000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	261222000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	186893000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	134461000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-143650000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-96125000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-54865000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8514000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1202000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1349000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	615000	USD
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	499000	USD
CY2019	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8514000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1670000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7134000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1273000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	40000	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	9085000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	USD
CY2021	hcat	Payments For Proceeds From Other Operating Activities PaymentsForProceedsFromOtherOperatingActivities	53000	USD
CY2020	hcat	Payments For Proceeds From Other Operating Activities PaymentsForProceedsFromOtherOperatingActivities	-116000	USD
CY2019	hcat	Payments For Proceeds From Other Operating Activities PaymentsForProceedsFromOtherOperatingActivities	54000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-102000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16448000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-127000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4442000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3667000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1596000	USD
CY2021	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	5202000	USD
CY2020	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	8243000	USD
CY2019	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	-86000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7637000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11459000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	77000	USD
CY2021	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3883000	USD
CY2020	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3414000	USD
CY2019	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3248000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23123000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26148000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32184000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	261363000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	189526000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	256007000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	186893000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	219069000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	50677000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	46763000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	101657000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10450000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7775000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2015000	USD
CY2021	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	6644000	USD
CY2020	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	1442000	USD
CY2019	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	384000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1373000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1248000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1935000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	22000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	14000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	62000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-139678000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82565000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-209602000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	245180000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	194649000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20350000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36264000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2656000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4844000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4273000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2978000	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6290000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1624000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1713000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	222482000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2021	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2020	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	21743000	USD
CY2019	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	57043000	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	21821000	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	47169000	USD
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	12073000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4610000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	264084000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	182609000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	231381000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	101273000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	73922000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10399000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91954000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18032000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28431000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193227000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91954000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18032000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6360000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4979000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5557000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	138000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	92000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	19000	USD
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	43104000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	72457000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	3000000	USD
CY2019	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2021	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	20083000	USD
CY2020	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	0	USD
CY2019	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	983000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2310000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	209000	USD
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	636000	USD
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	181000	USD
CY2019	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	0	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	520000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	78000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	1626000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	24456000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	581000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	1400000	USD
CY2021	hcat	Commission Payment Estimated Benefit Period CommissionPaymentEstimatedBenefitPeriod	P4Y
CY2021	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2020	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2019	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	180826000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ from those estimates.</span></div>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	30.60
CY2021	hcat	Revenue From Subscription Contract Termof Contract RevenueFromSubscriptionContractTermofContract	P3Y
CY2021	hcat	Revenue From Subscriptions Contract Allowed Termination Period RevenueFromSubscriptionsContractAllowedTerminationPeriod	P1Y
CY2021	hcat	Revenue From Subscriptions Contract Notice Required For Termination RevenueFromSubscriptionsContractNoticeRequiredForTermination	P90D
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	800000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1600000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2900000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	57600000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	49000000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32100000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	1400000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	500000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P12M
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	100000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	500000	USD
CY2021	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	USD
CY2019	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	USD
CY2020	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1200000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	499000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	99000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1600000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1400000	USD
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2700000	USD
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	4400000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	4300000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	4900000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to a concentration of credit risk consist principally of cash and cash equivalents, short-term investments, and accounts receivable. We deposit cash with high credit quality financial institutions which at times may exceed federally insured amounts. We have not experienced any losses on our deposits.</span></div>We perform ongoing credit evaluations of our customers’ financial condition and require no collateral from customers. We review the expected collectability of accounts receivable and record an allowance for credit losses based on the probability of future collections.
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	209409000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	173973000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-124485000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-90850000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	241926000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	188845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154941000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021Q4	us-gaap	Goodwill Goodwill	169972000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	107822000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	174305000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	69517000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	104788000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	136552000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37631000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	98921000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15900000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6300000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	32910000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	23793000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	17946000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11568000	USD
CY2019Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	400000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	9566000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	9005000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	104788000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34749000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22872000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11433000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10009000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23316000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12863000	USD
CY2021	us-gaap	Depreciation Depreciation	5500000	USD
CY2020	us-gaap	Depreciation Depreciation	2900000	USD
CY2019	us-gaap	Depreciation Depreciation	2900000	USD
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	7300000	USD
CY2020Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	1600000	USD
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2400000	USD
CY2020	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	700000	USD
CY2019	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	500000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	429741000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	88000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	429653000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	258290000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	258304000	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	800000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	500000	USD
CY2021Q4	hcat	Fair Value Measurement Aggregate Intrinsic Value FairValueMeasurementAggregateIntrinsicValue	19300000	USD
CY2021Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1800000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17430000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9838000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6295000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6672000	USD
CY2021Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23725000	USD
CY2020Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	16510000	USD
CY2021Q4	hcat	Lessee Operating Lease Lease Not Yet Commenced Liability LesseeOperatingLeaseLeaseNotYetCommencedLiability	31700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P11Y
CY2020Q2	us-gaap	Net Rentable Area NetRentableArea	64910	sqft
CY2020Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13000000	USD
CY2020Q3	us-gaap	Net Rentable Area NetRentableArea	53297	sqft
CY2020Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10800000	USD
CY2020Q3	hcat	Lessee Operating Lease Lease Not Yet Commenced Additional Liability LesseeOperatingLeaseLeaseNotYetCommencedAdditionalLiability	2800000	USD
CY2021Q3	hcat	Lessor Operating Lease Sublease Lease Term LessorOperatingLeaseSubleaseLeaseTerm	P2Y
CY2021Q3	hcat	Lessor Operating Lease Additional Sublease Option To Extend LessorOperatingLeaseAdditionalSubleaseOptionToExtend	P2Y
CY2021Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1800000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3425000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3364000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	602700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3073000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2931000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2881000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	14163000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	29837000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6168000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23669000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21133000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24729000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3425000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2622000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20244000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23669000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	26291000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y7M6D
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23669000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2021Q4	us-gaap	Share Price SharePrice	39.62
CY2019	hcat	Temporary Equity Additional Shares Authorized TemporaryEquityAdditionalSharesAuthorized	1077587	shares
CY2019	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	12100000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	hcat	Board Of Directors Number Of Classes BoardOfDirectorsNumberOfClasses	3	class
CY2021	hcat	Board Of Directors Term BoardOfDirectorsTerm	P3Y
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Shares Issued SharesIssued	52690019	shares
CY2021Q4	us-gaap	Shares Outstanding SharesOutstanding	52690019	shares
CY2020Q4	us-gaap	Shares Outstanding SharesOutstanding	43709237	shares
CY2020Q4	us-gaap	Shares Issued SharesIssued	43709237	shares
CY2020Q4	hcat	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Non Recourse ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonRecourse	332389	shares
CY2021Q4	hcat	Stockholders Vote StockholdersVote	1	vote
CY2019Q3	hcat	Convertible Stock Conversion Ratio ConvertibleStockConversionRatio	1
CY2019Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	23151481	shares
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-153210000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-115017000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-240922000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47494768	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47494768	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39540726	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39540726	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18741119	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18741119	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.91
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.91
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.86
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.86
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7333258	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7710407	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8351577	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65145000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37957000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17844000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65145000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37957000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17844000	USD
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	600000	USD
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	200000	USD
CY2019	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	0	USD
CY2019	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	USD
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	USD
CY2020	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P4Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3892936	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.58
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	123304540	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1738027	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39425	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.87
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2115484	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	59591457	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2115484	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	59591457	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1301262	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.55
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	37833348	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.31
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	67000000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	83200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6500000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6800000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9900000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8100000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2700000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1108974	shares
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-11000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	11000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	27000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-2000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	10000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	209000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	92000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	81000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	236000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	79000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	102000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5975000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1044000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	33000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1159000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-229000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7134000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1273000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	40000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6898000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1194000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	142000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.024
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.034
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.172
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.061
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.084
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.027
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.229
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.325
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.366
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.043
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.010
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6900000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1200000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7100000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1300000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	147674000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	106320000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	27391000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	22311000	USD
CY2021Q4	hcat	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	6044000	USD
CY2020Q4	hcat	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	6788000	USD
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	5780000	USD
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4746000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5430000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3344000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1153000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1505000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	750000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	423000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	571000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	665000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	416000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	308000	USD
CY2021Q4	hcat	Deferred Tax Assets Allowance For Bad Debt DeferredTaxAssetsAllowanceForBadDebt	404000	USD
CY2020Q4	hcat	Deferred Tax Assets Allowance For Bad Debt DeferredTaxAssetsAllowanceForBadDebt	305000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	70000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	60000	USD
CY2021Q4	hcat	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	0	USD
CY2020Q4	hcat	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	4882000	USD
CY2021Q4	hcat	Deferred Tax Assets Deferred Payroll DeferredTaxAssetsDeferredPayroll	0	USD
CY2020Q4	hcat	Deferred Tax Assets Deferred Payroll DeferredTaxAssetsDeferredPayroll	1108000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	195683000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	152765000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	175545000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	130080000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	20138000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	22685000	USD
CY2021Q4	hcat	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	11093000	USD
CY2020Q4	hcat	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	13864000	USD
CY2021Q4	hcat	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	5358000	USD
CY2020Q4	hcat	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	6289000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	2570000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1928000	USD
CY2021Q4	hcat	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	1102000	USD
CY2020Q4	hcat	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	478000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	58000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	49000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	15000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	126000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20196000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	22734000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	58000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	49000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	45500000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	31700000	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5578000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1816000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2372000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	122000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2228000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	957000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1392000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1534000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	401000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6848000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5578000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1816000	USD
CY2021	hcat	Contract With Customer Liability Revenue Recognized Percentage ContractWithCustomerLiabilityRevenueRecognizedPercentage	0.18
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	77000000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.80
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3800000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5300000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	241926000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	188845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154941000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-160108000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-116211000	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-59954000	USD

Files In Submission

Name	View Source	Status
0001636422-22-000011-index-headers.html	Edgar Link	pending
0001636422-22-000011-index.html	Edgar Link	pending
0001636422-22-000011.txt	Edgar Link	pending
0001636422-22-000011-xbrl.zip	Edgar Link	pending
exhibit106xofferletterdate.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hcat-20211231.htm	Edgar Link	pending
hcat-20211231.xsd	Edgar Link	pending
hcat-20211231_cal.xml	Edgar Link	unprocessable
hcat-20211231_def.xml	Edgar Link	unprocessable
hcat-20211231_g1.jpg	Edgar Link	pending
hcat-20211231_g2.gif	Edgar Link	pending
hcat-20211231_g3.gif	Edgar Link	pending
hcat-20211231_htm.xml	Edgar Link	completed
hcat-20211231_lab.xml	Edgar Link	unprocessable
hcat-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ye2021-10xkex211xsubsidiar.htm	Edgar Link	pending
ye2021-10xkex231xconsentof.htm	Edgar Link	pending
ye2021-10xkex311xcertifica.htm	Edgar Link	pending
ye2021-10xkex312xcertifica.htm	Edgar Link	pending
ye2021-10xkex321xcertifica.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCAT
Health Catalyst Inc Stock $hcat

2021 Q4 Form 10-K Financial Statement

#000163642222000011 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT Health Catalyst Inc Stock $hcat

2021 Q4 Form 10-K Financial Statement

#000163642222000011 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT
Health Catalyst Inc Stock $hcat